Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Assets (2017 - 2026)

Cogent Biosciences' Assets history spans 10 years, with the latest figure at $903.0 million for Q1 2026.

  • Quarterly Assets rose 218.19% to $903.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $903.0 million through Mar 2026, up 218.19% year-over-year, with the annual reading at $937.6 million for FY2025, 185.94% up from the prior year.
  • Assets came in at $903.0 million for Q1 2026, down from $937.6 million in the prior quarter.
  • In the past five years, Assets ranged from a high of $937.6 million in Q4 2025 to a low of $206.9 million in Q1 2022.
  • The 5-year median for Assets is $355.4 million (2023), against an average of $410.2 million.
  • Year-over-year, Assets crashed 40.39% in 2025 and then skyrocketed 218.19% in 2026.
  • Cogent Biosciences' Assets stood at $300.8 million in 2022, then grew by 4.2% to $313.4 million in 2023, then increased by 4.61% to $327.9 million in 2024, then soared by 185.94% to $937.6 million in 2025, then fell by 3.69% to $903.0 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Assets are $903.0 million (Q1 2026), $937.6 million (Q4 2025), and $425.9 million (Q3 2025).